Fosribnicotinamide

Fosribnicotinamide (β-nicotinamide mononucleotide) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of Fosribnicotinamide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].

Product Specifications

CAS Number

[1094-61-7]

Product Name Alternative

β-Nicotinamide mononucleotide; β-NM; NMN

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Endogenous Metabolite

Type

Natural Products

Related Pathways

Metabolic Enzyme/Protease

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/_beta_-Nicotinamide-mononucleotide.html

Purity

99.94

Solubility

H2O : 83.33 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@H](O)[C@@H](COP(O)([O-])=O)O[C@H]1[N+]2=CC=CC(C(N)=O)=C2

Molecular Formula

C11H15N2O8P

Molecular Weight

334.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Poddar SK, et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9 (1) :34. Published 2019 Jan 21.|[2]Lv H, et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion [published online ahead of print, 2020 Nov 3]. Cell Metab. 2020; S1550-4131 (20) 30554-4.|[3]Li J, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci U S A. 2019;116 (39) :19626-19634.|[4]Yoshino J, et al Nicotinamide mononucleotide, a key NAD (+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14 (4) :528-536.